Spectrum Bets On Marqibo In NHL With Low-Priced Talon Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
Spectrum gains an approved drug with the deal and aims for label expansion. Talon’s high-profile investors are counting on an increase in Spectrum share price and post-acquisition milestones to break even.